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component summary scores, the likely functional limitations,
mental health and health care utilization of patients with RLS.
RESULTS: RLS sufferers likely to currently be unable to work
due to their health were about three times that of US norm (22%
vs. 8%). About 22% of RLS sufferers were likely to lose their
job after one-year, compared with 3% norm. Moreover, RLS suf-
ferers at risk for diagnosis of clinical depression were over twice
that of US norm (40% vs. 18%). Additionally, they were also
more likely to report signiﬁcant stress than US norm (24% vs.
20%). Compared with US norm, RLS sufferers were more likely
to report limitations in daily activities, such as climbing several
ﬂights of stairs (71%) and lifting/carrying groceries (53%).
Finally, there were high rates of health care utilization for over
46% of RLS sufferers, compared with 13% for US norm. CON-
CLUSIONS: The sizable burden that RLS places on HRQOL is
associated with a likelihood of notably large functional limita-
tions, mental health stressors and health care resource use. There
is a signiﬁcant potential for RLS treatment to improve patients’
HRQOL and their associated functional and mental health, thus
potentially alleviating the impact on resource use.
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OBJECTIVES: To estimate the cost-effectiveness of dopamine
agonists such as pramipexole and piribedil on patients with early
Parkinson’s disease (PD). METHODS: Dopamine agonists have
been added to treatment of 40 early PD patients that received
amantadine and anticholinergics. A total of 18 patients (mean
age: 58.3 ± 7.7 years, mean duration of disease: 2.6 ± 1.1 years)
received pramipexole (mean dose: 2.4 ± 1.1mg) within one year
and 22 patients (mean age: 60.4 ± 5.6 years, mean duration of
disease: 3.2 ± 2.2 years) received piribedil (mean dose: 168.2 ±
24.6mg) within one year also. Clinical efﬁcacy was measured by
percentage reduction of Uniﬁed Parkinson Disease Rating Scale
(UPDRS). Only direct costs were estimated. Cost-effectiveness
ratio was deﬁned for both agonists. RESULTS: After one year 
of treatment by dopamine agonists, 40 early PD patients had
demonstrated signiﬁcant (p < 0.01) clinical improvement. Mean
percent UPDRS score reduction from basic treatment was 12.2%
in the pramipexole group of patients and 8.9% in the piribedil
group of patients. Patients had no adverse effects which could
lead to increase in cost of treatment. The mean cost for one-year
treatment of pramipexole was $1544.29 compared to $506.96
of piribedil. Cost-effectiveness ratio for pramipexole group was
$126.58 per 1% UPDRS score reduction, and $56.96 per 1%
UPDRS score reduction for the piribedil group. CONCLU-
SIONS: Treatment of early PD patients by dopamine agonists
such as pramipexol and piribedil resulted in signiﬁcant clinical
improvement. At the same time, use of piribedil is more cost-
effective than use of pramipexole for early PD patients.
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OBJECTIVES: To perform cost-utility analysis and calculated
Quality Adjusted Life Years (QALY) for dopamine agonists such
as Pramipexole and Piribedil on patients with early Parkinson’s
Disease (PD). METHODS: Basic treatment of 40 early PD
patients included amantadine and anticholinergics at least within
one year. Pramipexole (mean dose: 2.4 ± 1.1mg) was added to
basic treatment of 18 patients within one year, and Piribedil
(mean dose: 168.2 ± 24.6mg) was added to treatment of 22
patients within one year as well. To evaluate quality of life, we
included the 39-item Parkinson’s Disease Questionnaire (PDQ-
39) at baseline, one-year after basic treatment and one-year after
treatment by dopamine agonists. Utility was measured by per-
centage reduction of PDQ-39 and changes of summary index.
We carried out the cost-utility analysis and calculated QALY for
both agonists. Only direct costs were estimated. RESULTS:
Quality of life, characterized by summary index of PDQ-39,
changed compared with basic treatment from 0.516 (range 0–1)
up to 0.717 for Pramipexole group (mean percent PDQ-39 
score reduction was 20.1%). For the Piribedil group, summary
index of PDQ-39 changed compared with basic treatment from
0.618 up to 0.725 (mean percent PDQ-39 score reduction was
10.7%). For the Pramipexole group, mean cost of basic treat-
ment was $13.42 compared to $1544.29 of Pramipexole treat-
ment. For the Piribedil group, mean cost of basic treatment 
was $8.16 compared to $506.96 of Piribedil treatment. Cost-
utility for the Pramipexole group was $76.83 per 1% PDQ-39
score reduction and 47.38$ per 1% PDQ-39 score reduction 
for the Piribedil group. For early PD patients treated by
Pramipexole, QALY costs $1263.35 and $383.56 for patients
treated with Piribedil QALY. CONCLUSIONS: For early PD
patients, use of Piribedil is more cost-utility than use of
Pramipexole. QALY for Piribedil treatment costs much less than
Pramipexol treatment.
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OBJECTIVE: Parkinson’s Disease (PD) is a neurodegenerative
condition, with increasing resource use consequences as patients
progress. The purpose of this study was to investigate differences
in resource use for patients in different stages of PD.
METHODS: Data are drawn from a large cross-sectional obser-
vational study of patients receiving treatment for PD. A panel of
neurologists were asked to include the next ten patients con-
sulting with PD during a speciﬁed time period. Information col-
lected includes behavioural and attitudinal patient management
and resource use data. RESULTS: The study included 4234
patients treated by 428 doctors in the US and ﬁve European
countries. Disease state was measured by Hoehn and Yahr (HY)
scale, ranging from one (mild unilateral tremor, some rigidity,
minimal bradykinesia) to four (severe disability) and ﬁve (com-
plete immobility). Patients with HY score four and ﬁve were
grouped due to small numbers with HY ﬁve. There were no sig-
niﬁcant differences in HY distribution between the EU and US.
Likelihood of hospitalisation and admission for respite care is
much greater in Europe than the US (24.0% vs. 6.7%; p < 0.01
and 4.7% vs. 0.6%; p < 0.01). Hospital stay was also greater in
EU (16.3 vs. 6.7 days; p < 0.01). Likelihood of both hospitali-
sation and respite care correlated with worsening HY score.
Drug use patterns were similar in EU and US. Patients with HY
score of four and ﬁve took more drugs than patients with HY
one (mean number 2.15 vs. 1.15; p < 0.01). Likelihood of com-
bination therapy (particularly with levodopa) increased with
worsening HY score; at HY 4/5 levodopa therapy is much more
common than at HY1 (86% vs. 35%; p < 0.01). CONCLU-
